Skip to main content
PMC home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2008 Oct 1;5(4):528–534. doi: 10.1016/j.nurt.2008.08.012

Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: Treatment update

Andreas J Steck 1,✉, Adam Czaplinski 1, Susanne Renaud 1
PMCID: PMC4514701  PMID: 19019303

Summary

This review focuses on recent data regarding inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies. We describe both acute and chronic inflammatory neuropathies, and we discuss conditions ranging from mostly cell-mediated to antibody-mediated disorders. These diseases are characterized by proximal and distal sensory motor involvement. Treatments are based on immune-modulation and/or immune-suppression. Work-up sequence and therapeutical modes are discussed in the light of recently published data, with a special interest on new treatment modalities.

Key Words: Inflammation, antibody, immune-modulation, neuropathy, gammopathy

References

  • 1.Willison HJ. The immunobiology of Guillain-Barre syndromes. J Peripher Nerv Syst. 2005;10:94–112. doi: 10.1111/j.1085-9489.2005.0010202.x. [DOI] [PubMed] [Google Scholar]
  • 2.van Der Meche FG, van Doorn PA. Guillain-Barre Syndrome. Curr Treat Options Neurol. 2000;2:507–16. doi: 10.1007/s11940-000-0029-7. [DOI] [PubMed] [Google Scholar]
  • 3.Yuki N. Ganglioside mimicry and peripheral nerve disease. Muscle Nerve. 2007;35:691–711. doi: 10.1002/mus.20762. [DOI] [PubMed] [Google Scholar]
  • 4.Van der Meche FG, Van Doorn PA, Meulstee J, Jennekens FG. Diagnostic and classification criteria for the Guillain-Barre syndrome. Eur Neurol. 2001;45:133–9. doi: 10.1159/000052111. [DOI] [PubMed] [Google Scholar]
  • 5.van der Meche FG, Meulstee J, et al. Cytomegalovirus infection and Guillain-Barre syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barre Study Group. Neurology. 1996;47:668–73. doi: 10.1212/WNL.47.3.668. [DOI] [PubMed] [Google Scholar]
  • 6.van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med. 1992;326:1123–9. doi: 10.1056/NEJM199204233261705. [DOI] [PubMed] [Google Scholar]
  • 7.Hughes RA. Plasma exchange versus intravenous immunoglobulin for Guillain-Barre syndrome. Ther Apher. 1997;1:129–30. doi: 10.1111/j.1744-9987.1997.tb00027.x. [DOI] [PubMed] [Google Scholar]
  • 8.Kuwabara S, Ogawara K, Mizobuchi K, Mori M, Hattori T. Mechanisms of early and late recovery in acute motor axonal neuropathy. Muscle Nerve. 2001;24:288–91. doi: 10.1002/1097-4598(200102)24:2<288::AID-MUS150>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  • 9.Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain. 2007;130:2245–57. doi: 10.1093/brain/awm004. [DOI] [PubMed] [Google Scholar]
  • 10.van Koningsveld R, Schmitz PI, Meche FG, Visser LH, Meulstee J, van Doorn PA. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet. 2004;363:192–6. doi: 10.1016/S0140-6736(03)15324-X. [DOI] [PubMed] [Google Scholar]
  • 11.Radziwill AJ, Kuntzer T, Steck AJ. Immunopathology and treatments of Guillain-Barre syndrome and of chronic inflammatory demyelinating polyneuropathy. Rev Neurol (Paris) 2002;158(3):301–10. [PubMed] [Google Scholar]
  • 12.Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol. 2002;249:245–53. doi: 10.1007/s004150200000. [DOI] [PubMed] [Google Scholar]
  • 13.Recommendations on diagnostic strategies for chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2008;79:115–8. [DOI] [PubMed]
  • 14.Sghirlanzoni A, Solari A, Ciano C, Mariotti C, Fallica E, Pareyson D. Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients. Neurol Sci. 2000;21:31–7. doi: 10.1007/s100720070116. [DOI] [PubMed] [Google Scholar]
  • 15.Uzenot D, Azulay JP, Pouget J. Treatment’s initiation in chronic inflammatory demyelinating polyradiculopathy (CIDP) Rev Neurol (Paris) 2007;163:3S68–76. doi: 10.1016/S0035-3787(07)92163-3. [DOI] [PubMed] [Google Scholar]
  • 16.Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989;46:878–84. doi: 10.1001/archneur.1989.00520440064022. [DOI] [PubMed] [Google Scholar]
  • 17.Meucci N, Cappellari A, Barbieri S, Scarlato G, Nobile-Orazio E. Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 1997;63:765–9. doi: 10.1136/jnnp.63.6.765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Nobile-Orazio E. Treatment of dys-immune neuropathies. J Neurol. 2005;252:385–95. doi: 10.1007/s00415-005-0805-0. [DOI] [PubMed] [Google Scholar]
  • 19.Cornblath DR, Chaudhry V, Griffin JW. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol. 1991;30:104–6. doi: 10.1002/ana.410300119. [DOI] [PubMed] [Google Scholar]
  • 20.van Doorn PA, Vermeulen M, Brand A, Mulder PG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol. 1991;48:217–20. doi: 10.1001/archneur.1991.00530140113024. [DOI] [PubMed] [Google Scholar]
  • 21.Kieseier BC, Meyer Zu Hörste G, Lehmann HC, Gold R, Hartung HP. Intravenous immunoglobulins in the treatment of immune neuropathies. Curr Opin Neurol. 2008;21:555–62. doi: 10.1097/WCO.0b013e32830efc03. [DOI] [PubMed] [Google Scholar]
  • 22.Choudhary PP, Hughes RA. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. Qjm. 1995;88:493–502. [PubMed] [Google Scholar]
  • 23.Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain. 1996;119:1055–66. doi: 10.1093/brain/119.4.1055. [DOI] [PubMed] [Google Scholar]
  • 24.Walk D, Li LY, Parry GJ, Day JW. Rapid resolution of quadriplegic CIDP by combined plasmapheresis and IVIg. Neurology. 2004;62:155–6. doi: 10.1212/WNL.62.1.155. [DOI] [PubMed] [Google Scholar]
  • 25.Czaplinski A, Steck AJ. Immune mediated neuropathies—an update on therapeutic strategies. J Neurol. 2004;251:127–37. doi: 10.1007/s00415-004-0323-5. [DOI] [PubMed] [Google Scholar]
  • 26.Hughes RA. Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy. Rev Neurol (Paris) 2002;158:S32–S36. [PubMed] [Google Scholar]
  • 27.Axelson HW, Oberg G, Askmark H. Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP. J Neurol Neurosurg Psychiatry. 2008;79:612–4. doi: 10.1136/jnnp.2007.128694. [DOI] [PubMed] [Google Scholar]
  • 28.Roth G, Rohr J, Magistris MR, Ochsner F. Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Evolution to tetraplegia. Eur Neurol. 1986;25:416–23. doi: 10.1159/000116045. [DOI] [PubMed] [Google Scholar]
  • 29.Parry GJ, Clarke S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve. 1988;11:103–7. doi: 10.1002/mus.880110203. [DOI] [PubMed] [Google Scholar]
  • 30.Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988;24:73–8. doi: 10.1002/ana.410240113. [DOI] [PubMed] [Google Scholar]
  • 31.Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve. 2005;31:663–80. doi: 10.1002/mus.20296. [DOI] [PubMed] [Google Scholar]
  • 32.Verschueren A, Azulay JP, Attarian S, Boucraut J, Pellissier JF, Pouget J. Lewis-Sumner syndrome and multifocal motor neuropathy. Muscle Nerve. 2005;31:88–94. doi: 10.1002/mus.20236. [DOI] [PubMed] [Google Scholar]
  • 33.Pestronk A, Choksi R. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates. Neurology. 1997;49:1289–92. doi: 10.1212/WNL.49.5.1289. [DOI] [PubMed] [Google Scholar]
  • 34.Taylor BV, Gross L, Windebank AJ. The sensitivity and specificity of anti-GM1 antibody testing. Neurology. 1996;47:951–5. doi: 10.1212/WNL.47.4.951. [DOI] [PubMed] [Google Scholar]
  • 35.Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve. 2001;24:311–24. doi: 10.1002/1097-4598(200103)24:3<311::AID-MUS1001>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  • 36.Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology. 2000;55:1256–62. doi: 10.1212/WNL.55.9.1256. [DOI] [PubMed] [Google Scholar]
  • 37.Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain. 2001;124:145–53. doi: 10.1093/brain/124.1.145. [DOI] [PubMed] [Google Scholar]
  • 38.Van den Berg-Vos RM, Franssen H, Wokke JH, Van Es HW, Van den Berg LH. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol. 2000;48:919–26. doi: 10.1002/1531-8249(200012)48:6<919::AID-ANA13>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  • 39.Azulay JP, Rihet P, Pouget J, et al. Long term follow up of multifocal motor neuropathy with conduction block under treatment. J Neurol Neurosurg Psychiatry. 1997;62:391–4. doi: 10.1136/jnnp.62.4.391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Nobile-Orazio E, Terenghi F. IVIg in idiopathic autoimmune neuropathies: analysis in the light of the latest results. J Neurol. 2005;252(Suppl 1):I7–3. doi: 10.1007/s00415-005-1103-6. [DOI] [PubMed] [Google Scholar]
  • 41.Ruegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology. 2004;63:2178–9. doi: 10.1212/01.WNL.0000145706.04340.25. [DOI] [PubMed] [Google Scholar]
  • 42.Nobile-Orazio E, Cappellari A, Meucci N, et al. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry. 2002;72:761–6. doi: 10.1136/jnnp.72.6.761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Katz JS, Wolfe GI, Bryan WW, Jackson CE, Amato AA, Barohn RJ. Electrophysiologic findings in multifocal motor neuropathy. Neurology. 1997;48:700–7. doi: 10.1212/WNL.48.3.700. [DOI] [PubMed] [Google Scholar]
  • 44.Umapathi T, Hughes RA, Nobile-Orazio E, Leger JM. Immunosuppressive treatment for multifocal motor neuropathy. Cochrane Database Syst Rev 2002:CD003217. [DOI] [PubMed]
  • 45.Abbruzzese M, Reni L, Schenone A, Mancardi GL, Primavera A. Multifocal motor neuropathy with conduction block after Campylobacter jejuni enteritis. Neurology. 1997;48:544–544. doi: 10.1212/WNL.48.2.544. [DOI] [PubMed] [Google Scholar]
  • 46.Hausmanowa-Petrusewicz I, Rowinska-Marcinska K, Kopec A. Chronic acquired demyelinating motor neuropathy. Acta Neurol Scand. 1991;84:40–5. doi: 10.1111/j.1600-0404.1991.tb04900.x. [DOI] [PubMed] [Google Scholar]
  • 47.Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1994;57:778–83. doi: 10.1136/jnnp.57.7.778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Brannagan TH, Alaedini A, Gladstone DE. High-dose cyclo-phosphamide without stem cell rescue for refractory multifocal motor neuropathy. Muscle Nerve. 2006;34:246–50. doi: 10.1002/mus.20524. [DOI] [PubMed] [Google Scholar]
  • 49.Piepers S, Van den Berg-Vos R, Van der Pol WL, Franssen H, Wokke J, Van den Berg L. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain. 2007;130:2004–10. doi: 10.1093/brain/awm144. [DOI] [PubMed] [Google Scholar]
  • 50.Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, Wokke JH, Van den Berg LH. Multifocal motor neuropathy. Lancet Neurol. 2005;4:309–19. doi: 10.1016/S1474-4422(05)70074-0. [DOI] [PubMed] [Google Scholar]
  • 51.Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108:2520–30. doi: 10.1182/blood-2006-03-001164. [DOI] [PubMed] [Google Scholar]
  • 52.Kelly JJ, Kyle RA, O’Brien PC, Dyck PJ. Prevalence of monoclonal protein in peripheral neuropathy. Neurology. 1981;31:1480–3. doi: 10.1212/WNL.31.11.1480. [DOI] [PubMed] [Google Scholar]
  • 53.Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362–9. doi: 10.1056/NEJMoa054494. [DOI] [PubMed] [Google Scholar]
  • 54.Benedetti L, Briani C, Grandis M, et al. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst. 2007;12:102–7. doi: 10.1111/j.1529-8027.2007.00129.x. [DOI] [PubMed] [Google Scholar]
  • 55.Broglio L, Lauria G. Worsening after rituximab treatment in antimag neuropathy. Muscle Nerve. 2005;32:378–9. doi: 10.1002/mus.20386. [DOI] [PubMed] [Google Scholar]
  • 56.Noronha V, Fynan TM, Duffy T. Flare in neuropathy following rituximab therapy for Waldenstrom’s macroglobulinemia. J Clin Oncol. 2006;24:e3–e3. doi: 10.1200/JCO.2005.04.6474. [DOI] [PubMed] [Google Scholar]
  • 57.Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve. 2003;27:611–5. doi: 10.1002/mus.10359. [DOI] [PubMed] [Google Scholar]
  • 58.Steck AJ, Stalder AK, Renaud S. Anti-myelin-associated glycoprotein neuropathy. Curr Opin Neurol. 2006;19:458–63. doi: 10.1097/01.wco.0000245368.36576.0d. [DOI] [PubMed] [Google Scholar]
  • 59.Wilson HC, Lunn MP, Schey S, Hughes RA. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry. 1999;66:575–80. doi: 10.1136/jnnp.66.5.575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Oka N, Kusaka H, Kusunoki S, et al. IgM M-protein with antibody activity against gangliosides with disialosyl residue in sensory neuropathy binds to sensory neurons. Muscle Nerve. 1996;19:528–0. doi: 10.1002/(SICI)1097-4598(199604)19:4<528::AID-MUS15>3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]
  • 61.Willison HJ, O’Leary CP, Veitch J, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain. 2001;124:1968–77. doi: 10.1093/brain/124.10.1968. [DOI] [PubMed] [Google Scholar]
  • 62.Lo YL. Clinical and immunological spectrum of the Miller Fisher syndrome. Muscle Nerve. 2007;36:615–27. doi: 10.1002/mus.20835. [DOI] [PubMed] [Google Scholar]
  • 63.Gong Y, Tagawa Y, Lunn MP, et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain. 2002;125:2491–506. doi: 10.1093/brain/awf258. [DOI] [PubMed] [Google Scholar]
  • 64.Kusunoki S, Chiba A, Tai T, Kanazawa I. Localization of GM1 and GD1b antigens in the human peripheral nervous system. Muscle Nerve. 1993;16:752–6. doi: 10.1002/mus.880160710. [DOI] [PubMed] [Google Scholar]
  • 65.Kusunoki S, Shimizu J, Chiba A, Ugawa Y, Hitoshi S, Kanazawa I. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol. 1996;39:424–31. doi: 10.1002/ana.410390404. [DOI] [PubMed] [Google Scholar]
  • 66.Miralles GD, O’Fallon JR, Talley NJ. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med. 1992;327:1919–23. doi: 10.1056/NEJM199212313272705. [DOI] [PubMed] [Google Scholar]
  • 67.Dispenzieri A. POEMS Syndrome. Hematology Am Soc Hematol Educ Program 2005:360–7. [DOI] [PubMed]
  • 68.Sung JY, Kuwabara S, Ogawara K, Kanai K, Hattori T. Patterns of nerve conduction abnormalities in POEMS syndrome. Muscle Nerve. 2002;26:189–93. doi: 10.1002/mus.10182. [DOI] [PubMed] [Google Scholar]
  • 69.Vital C, Vital A, Ferrer X, et al. Crow-Fukase (POEMS) syndrome: a study of peripheral nerve biopsy in five new cases. J Peripher Nerv Syst. 2003;8:136–44. doi: 10.1046/j.1529-8027.2003.03019.x. [DOI] [PubMed] [Google Scholar]
  • 70.Michel JL, Gaucher-Hugel AS, Reynier C, et al. POEMS syndrome: imaging of skeletal manifestations, a study of 8 cases. J Radiol. 2003;84(4):393–7. [PubMed] [Google Scholar]
  • 71.Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101:2496–506. doi: 10.1182/blood-2002-07-2299. [DOI] [PubMed] [Google Scholar]
  • 72.Gherardi RK, Belec L, Soubrier M, et al. Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood. 1996;87:1458–65. [PubMed] [Google Scholar]
  • 73.Scarlato M, Previtali SC, Carpo M, et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain. 2005;128:1911–20. doi: 10.1093/brain/awh519. [DOI] [PubMed] [Google Scholar]
  • 74.Silberman J, Lonial S. Review of peripheral neuropathy in plasma cell disorders. Hematol Oncol. 2008;26:55–65. doi: 10.1002/hon.845. [DOI] [PubMed] [Google Scholar]
  • 75.Rotta FT, Bradley WG. Marked improvement of severe polyneuropathy associated with multifocal osteosclerotic myeloma following surgery, radiation, and chemotherapy. Muscle Nerve. 1997;20:1035–7. doi: 10.1002/(SICI)1097-4598(199708)20:8<1035::AID-MUS16>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  • 76.Peggs KS, Paneesha S, Kottaridis PD, et al. Peripheral blood stem cell transplantation for POEMS syndrome. Bone Marrow Transplant. 2002;30:401–4. doi: 10.1038/sj.bmt.1703670. [DOI] [PubMed] [Google Scholar]
  • 77.Dietrich PY, Duchosal MA. Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome. Ann Oncol. 2008;19:595–595. doi: 10.1093/annonc/mdm602. [DOI] [PubMed] [Google Scholar]
  • 78.Gemignani F, Melli G, Inglese C, Marbini A. Cryoglobulinemia is a frequent cause of peripheral neuropathy in undiagnosed referral patients. J Peripher Nerv Syst. 2002;7:59–64. doi: 10.1046/j.1529-8027.2002.02007.x. [DOI] [PubMed] [Google Scholar]
  • 79.Saadoun D, Delluc A, Piette JC, Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol. 2008;20:23–8. doi: 10.1097/BOR.0b013e3282f1330c. [DOI] [PubMed] [Google Scholar]
  • 80.Braun A, Neumann T, Oelzner P, et al. Cryoglobulinaemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab. Rheumatol Int. 2008;28:503–6. doi: 10.1007/s00296-007-0462-y. [DOI] [PubMed] [Google Scholar]
  • 81.Dispenzieri A, Gorevic PD. Cryoglobulinemia. Hematol Oncol Clin North Am. 1999;13:1315–49. doi: 10.1016/S0889-8588(05)70129-5. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES